OncLive TV

Sairah Ahmed, MD, explains the rationale for evaluating NTKR-255 after CAR T-cell therapy in relapsed/refractory large B-cell lymphoma.

Richard Lee, MD, FASCO, discusses the role of integrative medicine in oncology care.

Raajit Rampal, MD, discusses typical clinical applications of the 4 FDA-approved JAK inhibitors for the treatment of patients with myelofibrosis.

Rachel N. Grisham, MD, discusses efficacy and tolerability data from the phase 2 ENGOT-OV60/GOG-3052/RAMP 201 subgroup analysis.

Bhagirathbhai Dholaria, MBBS, discusses the rationale and evolving investigation of P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma.

Hideaki Bando, MD, PhD, discusses the safety of trifluridine/tipiracil in patients with MRD following resection of CRC.

Mauricio Escobar, MD, discusses CDK4/6 inhibitor selection based on retrospective real-world analyses in HR-positive metastatic breast cancer.

María-Victoria Mateos, MD, PhD, discusses next steps for evaluating the role of cilta-cel in lenalidomide-refractory and other multiple myeloma subtypes.

Panagiotis A. Konstantinopoulos, MD, PhD, discusses CRs achieved with letrozole, abemaciclib, and metformin in ER–positive endometriod endometrial cancer.

Heinz-Josef Lenz, MD, discusses data from the CheckMate 8HW trial that led to the FDA approval of nivolumab plus ipilimumab for dMMR/MSI-H metastatic CRC.

Ecaterina Dumbrava, MD, discusses the rationale and clinical development of rezatapopt in ovarian cancer and other solid tumors harboring TP53 Y220C mutations.

Evan Ya-Wen Yu, MD, discusses considerations surrounding the tolerability of PARP inhibitors and how their adverse effect profiles influence treatment decisions in metastatic prostate cancer.

Nirav Shah, MD, discusses the clinical implications and future directions for zamto-cel in patients with relapsed/refractory diffuse large B-cell lymphoma.

Lor Randall, MD, FACS, on a global survey regarding enrollment criteria for a trial evaluating surgical resection for proximal femur metastases.

William Kelly, MD, discusses the safety and efficacy signals seen with sacituzumab govitecan in a phase 2 study of patients with recurrent glioblastoma.

Kelly E. McCann, MD, PhD, discusses the benefit of using TKI combinations for patients with HER2-positive breast cancer and brain metastases.

Jeffrey Zonder, MD, discusses the current epidemiological landscape of multiple myeloma in the United States.

Paolo Ghia, MD, PhD, discusses long-term data for fixed-duration ibrutinib plus venetoclax in chronic lymphocytic leukemia.

Tashanna K. Myers, MD, discusses the importance of telling patients with ovarian cancer about the HRQOL outcomes associated with mirvetuximab soravtansine.

Jian Zhang, MD, details the rationale of evaluating SIM0270 plus everolimus in patients with ER-positive/HER2-negative advanced breast cancer.

Mikkael A. Sekeres, MD, discusses the implications of a study that found associations between smoking intensity and disease progression in MDS.

R. Lor Randall, MD, FACS, discusses how immunodeficient mouse models support mechanistic and therapeutic discovery in rare sarcoma subtypes.

Filippo Pietrantonio, MD, highlights the future directions of assessing amivantamab with or without chemotherapy in patients with colorectal cancer.

Benjamin Herzberg, MD the clinical similarities and key distinctions between sotorasib and adagrasib for KRAS G12C+ NSCLC.

Martin Dreyling, MD, discusses the expanding role of BTK inhibitors in the treatment of mantle cell lymphoma.

Rachel N. Grisham, MD, discusses the safety of avutometinib plus defactinib in patients with advanced or recurrent gynecologic mesonephric cancer.

Laurence Albiges, MD, PhD, discusses the clinical implications of preliminary efficacy data observed with belzutifan plus lenvatinib in advanced ccRCC.

Evan Y. Yu, MD, discusses the potential utility of AR degradation, mutation inhibition, and suppression for patients with metastatic prostate cancer.

Donal McLornan, MBBCh, MRCP, PhD, FRCPath, discusses future research directions for an EBMT machine learning model for identifying and stratifying transplant risk in myelofibrosis.

Kiavasch Mohammad Nejad Farid, MD, discusses the efficacy of MDC-CAR-BCMA001 in relapsed/refractory multiple myeloma and systemic light chain (AL) amyloidosis.